Antybiotykooporność i mechanizmy jej powstawania w przypadku zakażeń Mycoplasma bovis u bydła

• Autorzy: Szacawa E. , Horecka A. , Bednarek D. , Niemczuk K.

Warianty tytułu

EN

Antibiotic resistance and the mechanisms of its development in the case of Mycoplasma bovis infection in cattle

• Języki publikacji: PL

Abstrakty

EN

Mycoplasma bovis is the smallest known bacterium that does not have a cell wall. It is therefore resistant to some antibiotics that inhibit the synthesis of the cell structure. Little is known about the mechanisms of antibiotic resistance in M. bovis, since it has no plasmids and there are insufficient data about the role of the biofilm formation by these bacteria. Previous studies have shown that the development of antibiotic resistance is due to gene mutations. Antibiotics generally considered as effective against M. bovis infection are macrolides, fluoroquinolones, tetracyclines, lincosamides, aminoglycosides, and chloramphenicol. Several recent studies, however, indicate that the efficacy of tetracyclines, macrolides, and lincosamides has diminished. Increased resistance to erythromycin, spectinomycin, and tilmicosin, antibiotics commonly used in the treatment of M. bovis infections, has also been reported. Among field strains of M. bovis no resistance or rare resistance has only been observed for enrofloxacin, florfenicol, tylosin, and tulathromycin. Considering the rapidly growing antibiotic resistance of the isolated strains of M. bovis, it is necessary to search for alternative compounds that could effectively inhibit these bacteria.

Słowa kluczowe

PL

bydlo; infekcja bakteryjna; mikoplazmy; Mycoplasma bovis; opornosc na antybiotyki; mechanizmy opornosciowe

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2014
• Tom: 70
• Numer: 07
• Opis fizyczny: s.396-399,tab.,bibliogr.

Twórcy

autor

Szacawa E.

• Zakład Chorób Bydła i Owiec, Państwowy Instytut Weterynaryjny - Państwowy Instytut Badawczy, Al.Partyzantów 57, 24-100 Puławy

autor

Horecka A.

• Katedra i Zakład Chemii Medycznej, Uniwersytet Medyczny w Lublinie, ul.Chodźki 4A, 20-093 Lublin

autor

Bednarek D.

• Zakład Chorób Bydła i Owiec, Państwowy Instytut Weterynaryjny - Państwowy Instytut Badawczy, Al.Partyzantów 57, 24-100 Puławy

autor

Niemczuk K.

• Zakład Chorób Bydła i Owiec, Państwowy Instytut Weterynaryjny - Państwowy Instytut Badawczy, Al.Partyzantów 57, 24-100 Puławy

Bibliografia

• 1. Alavi-Shoushtari S. M., Ahmadi M., Shahvarpour S., Kolahian S.: Effects of tiamulin, neomycin, tetracycline, fluorophenicol, penicillin G, Linco-Spectin, erythromycin and oxytetracycline on controlling bacterial contaminations of the river buffalo (Buballus bubalis) semen. Pak. J. Biol. Sci. 2007, 10, 3200-3204.
• 2. Ayling R., Nicholas R., McAuliffe L.: Mycoplasma diseases of ruminants. CAB International. 2008, 1-239.
• 3. Ayling R. D., Baker S. E., Peek M. L., Simon A. J., Nicholas R. A. J.: Comparison of in vitro activity of danofloxacin, florfenicol, oxytetracycline, spectinomycin and tilmicosin against recent field isolates of Mycoplasma bovis. Vet. Rec. 2000, 146, 745-747.
• 4. Ayling R. D., Nicholas R. A. J.: Zastosowanie antybiotyków w leczeniu infekcji wywołanych przez mykoplazmy u bydła, [w:] Najważniejsze czynniki etiologiczne, patogeneza i najnowsze trendy w profilaktyce i terapii syndromu oddechowego bydła (BRD). Monografia pod red. Bednarek D. PIWet-PIB, Puławy 2008, 42-47.
• 5. Breton M., Tardy F., Dordet-Frisoni E., Sagne E., Mick V., Renaudin J., Sirand-Pugnet P., Citti C., Blanchard A.: Distribution and diversity of mycoplasma plasmids: lessons from cryptic genetic elements. BMC Microbiol. 2012, 12, 1-15.
• 6. Cress B. F., Greene Z. R., Linhardt R. J., Koffas A. G. K.: Draft genome sequence of Escherichia coli strain ATCC 23506 (serovar O10:K5:H4). Genome Announc. 2013, 1, 1-2.
• 7. Francoz D., Fortin M., Fecteau G., Messier S.: Determination of Mycoplasma bovis susceptibilities against six antimicrobial agents using the E test method. Vet. Microbiol. 2005, 105, 57-64.
• 8. Gerchman I., Levisohn S., Mikula I., Lysnyansky I.: In vitro antimicrobial susceptibility of Mycoplasma bovis isolated in Israel from local and imported cattle. Vet. Microbiol. 2009, 137, 268-275.
• 9. Hannan P. C. T.: Guidelines and recommendations for antimicrobial minimum inhibitory concentration (MIC) testing against veterinary mycoplasma species. Vet. Res. 2000, 31, 73-395.
• 10. Herman Z., Kostowski W.: Farmakologia. Podstawy farmakoterapii. Wydawnictwo Lekarskie PZWL, Warszawa 2008.
• 11. Hirose K., Kobayashi H., Ito N., Kawasaki Y., Zako M., Kotani K., Ogawa H., Sato H.: Isolation of Mycoplasmas from nasal swabs of calves affected with respiratory diseases and antimicrobial susceptibility of their isolates. J. Vet. Med. 2003, B 50, 347-351.
• 12. Lysnyansky I., Mikula I., Gerchman I., Levisohn S.: Rapid detection of a point mutation in the parC gene associated with decreased susceptibility to fluoroquinolones in Mycoplasma bovis. Antimicrob. Agents Chemoth. 2009, 53, 4911-4914.
• 13. Mah T.-F. C., O’Toole G. A.: Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001, 9, 34-39.
• 14. Maunsell F. P., Donovan G. A., Risco C., Brown M. B.: Field evaluation of a Mycoplasma bovis bacterin in young dairy calves. Vaccine 2009, 27, 2781-2788.
• 15. McAuliffe L., Ellis R. J., Mile K., Ayling R. D., Nicholas A. J.: Biofilm formation by mycoplasma species and its role in environmental persistence and survival. Microbiology 2006, 152, 913-922.
• 16. Nicholas R. A. J.: The other M. bovis: Mycoplasma bovis. UK Vet. 2010, 15, 1-3.
• 17. Olszewska M.: Mechanizm działania i zastosowanie oksytetracykliny w chorobach skóry. Wiad. Lek. 2006, LIX, 11-12.
• 18. Poumarat F., Le Grand D., Philippe S., Calavas D., Schelcher F., Cabanié P., Tessier P., Navetat H.: Efficcacy of spectinomycin against Mycoplasma bovis induced pneumonia in conventionally reared calves. Vet. Microbiol. 2001, 80, 23-35.
• 19. Razin S., Yogev D., Naot Y.: Molecular biology and pathogenicity of Mycoplasmas. Microbiol. Mol. Biol. Rev. 1998, 64, 1094-1156.
• 20. Reinhardt A. K., Bebear C. M., Kobisch M., Kempf I., Gautier-Bouchardon A. V.: Characterization of mutations in DNA gyrase and topoisomerase IV involved in quinolone resistance of Mycoplasma gallisepticum mutants obtained in vitro. Antimicrob. Agents Chemoth. 2002, 46, 590-593.
• 21. Roliński Z.: Farmakologia i farmakoterapia weterynaryjna. Państwowe Wydawnictwo Rolnicze i Leśne, Warszawa 2001.
• 22. Rosenbush R. F., Kinyon J. M., Apley M., Funk N. D., Smith S., Hoffman L. J.: In vitro antimicrobial inhibition profiles of Mycoplasma bovis isolates recovered from various regions of the United States from 2002 to 2003. J. Vet. Diagn. Invest. 2005, 17, 436-441.
• 23. Shabat M. B., Mikula I., Gerchman I., Lysnyansky I.: Development and evaluation of a novel single-nucleotide-polymorphism real-time PCR assay for rapid detection of fluoroquinolone-resistant Mycoplasma bovis. J. Clin. Microbiol. 2010, 48, 2909-2915.
• 24. Siugzdaite J., Gabinaitiene A., Kerziene S.: Susceptibility of Mycoplasma bovis field isolates to antimicrobial agents. Vet. Med. 2012, 57, 575-582.
• 25. Soehnlen M. K., Tran M. A., Lysczek H. R., Wolfgang D. R., Jayarao B. M.: Identification of a novel small molecule antimicrobials targeting Mycoplasma bovis. J. Antimicrob. Chemother. 2011, 66, 574-577.
• 26. Solecka J., Ziemska J., Rajnisz A, Laskowska A., Guśpiel A.: Promieniowce – występowanie i wytwarzanie związków biologicznie czynnych. Post. Mikrobiol. 2013, 52, 83-91.
• 27. Uemura R., Sueyoshi M., Nagamoto H.: Antimicrobial susceptibilities of four species of Mycoplasma isolated in 2008 and 2009 from cattle in Japan. J. Vet. Med. Sci. 2010, 72, 1661-1663.
• 28. Wise K. S., Calcutt M. J., Foecking M. F., Röske K., Madupu R., Methé B. A.: Complete genome sequence of Mycoplasma bovis type strain PG 45 (ATCC 25523). Infect. Immun. 2011, 982-983.